Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.

PloS one - 1 Jan 2012

Byron Sara A, Gartside Michael, Powell Matthew A, Wellens Candice L, Gao Feng, Mutch David G, Goodfellow Paul J, Pollock Pamela M

Abstract excerpt

Mutations in multiple oncogenes including KRAS, CTNNB1, PIK3CA and FGFR2 have been identified in endometrial cancer. The aim of this study was to provide insight into the clinicopathological features associated with patterns of mutation in these genes, a necessary step in planning targeted therapies for endometrial cancer. 466 endometrioid endometrial tumors were tested for mutations in FGFR2, KRAS, CTNNB1, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Endometrial Neoplasms

Share to Microsatellite Instability

Share to Phosphatidylinositol 3-Kinases

Share to Proportional Hazards Models

Share to Receptor, Fibroblast Growth Factor, Type 2

Source

Open in PubMed Open full text

Identifiers

PMID: 22383975
DOI: 10.1371/journal.pone.0030801
PMCID: PMC3285611

Genes

KRAS
FGFR2
CTNNB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.PMID 22383975Read ↗

Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers.Semantic proximity Read ↗

High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently MutatedSemantic proximity Read ↗

KRAS mutations in endometrial cancers: Possible prognostic and treatment implications.Semantic proximity Read ↗

The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.Semantic proximity Read ↗

Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma.Semantic proximity Read ↗

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.Semantic proximity Read ↗

K- ras gene point mutations in human endometrial carcinomas: correlation with clinicopathological features and patients' outcomeSemantic proximity Read ↗

Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.Semantic proximity Read ↗

Molecular profiles of benign and (pre)malignant endometrial lesions.Semantic proximity Read ↗

PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas.Semantic proximity Read ↗

FGFR2 as a molecular target in endometrial cancer.Semantic proximity Read ↗

A Combined Morphologic and Molecular Approach to Retrospectively Identify KRAS-Mutated Mesonephric-like Adenocarcinomas of the EndometriumSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.